Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials

Fineline Cube Feb 9, 2026
Company Drug

InnoCare Pharma’s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials

Fineline Cube Feb 9, 2026
Company Drug

CanSino Biologics’ DTcP Vaccine for Infants Gains Priority Review in China

Fineline Cube Feb 8, 2025

China-based vaccines specialist CanSino Biologics Inc. (HKG: 6185) announced that the New Drug Application (NDA)...

Company Drug

Keymed Biosciences’ Kangyueda Gains NMPA Approval for Seasonal Allergic Rhinitis

Fineline Cube Feb 8, 2025

China-based Keymed Biosciences Inc. (HKG: 2162) announced that it has received another indication approval from...

Company Drug

Novo Nordisk’s Mim8 Shows Promise in Hemophilia A Trial with 98% Caregiver Preference

Fineline Cube Feb 8, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) released interim results from the Phase III FRONTIER3 study,...

Company

RemeGen’s Executive Director He Ruyi Resigns for Career Development

Fineline Cube Feb 8, 2025

China-based pharmaceutical firm RemeGen (HKG: 9995) announced the resignation of Mr. He Ruyi, Executive Director...

Company Drug

Biokin Pharmaceutical’s BL-M07D1 Gains NMPA Approval for Phase III Study

Fineline Cube Feb 8, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that it has received approval from...

Company Drug

AbbVie’s Emblaveo Wins FDA Approval for Complicated Intra-Abdominal Infections

Fineline Cube Feb 8, 2025

US-based pharmaceutical giant AbbVie (NYSE: ABBV) announced that it has received marketing approval from the...

Company Drug

Zhongsheng Pharma Gains FDA Approval for Phase II Study of RAY1225

Fineline Cube Feb 8, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval from...

Company Medical Device

Siemens Healthineers Posts Strong Q1 Results with 5.7% Revenue Growth

Fineline Cube Feb 8, 2025

Germany-based Siemens Healthineers AG (ETR: SHL) released its results for the first quarter of fiscal...

Company Drug

Bio-Thera’s Biosimilars BAT2306 and BAT2506 Accepted for Review by NMPA and EMA

Fineline Cube Feb 8, 2025

China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that the market filings for its biosimilars BAT2306...

Company Deals

Bain Capital to Acquire Tanabe Pharma in JPY 510 Billion Deal

Fineline Cube Feb 8, 2025

Bain Capital is set to acquire Mitsubishi Tanabe Pharma Corporation (Tanabe Pharma) in a carve-out...

Company Deals

Henlius Biotech Licenses HLX15 to Dr. Reddy’s for US and European Markets

Fineline Cube Feb 7, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced a licensing deal with India-headquartered Dr. Reddy’s...

Company

Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches

Fineline Cube Feb 7, 2025

China-based Innovent Biologics Inc. (HKG: 1801) reported product sales of over RMB 2 billion (USD...

Company

Bristol-Myers Squibb Posts 8% Q4 Revenue Growth, Driven by Opdivo and New Products

Fineline Cube Feb 7, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) reported an 8% year-on-year (YOY) increase in revenues to USD...

Company Drug

CanSino’s Tetanus Vaccine NDA Accepted for Review by NMPA

Fineline Cube Feb 7, 2025

China-based vaccines specialist CanSino Biotechnology Inc. (HKG: 6185) announced that the National Medical Products Administration...

Company Drug

Huahai Pharma Set to Launch IL-17 Antibody HB0017 Clinical Study for HS

Fineline Cube Feb 7, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) is poised to initiate a clinical study...

Company Drug

Hotgen Biotech Gains NMPA Approval for AA001 Clinical Trials in Alzheimer’s Disease

Fineline Cube Feb 7, 2025

China’s Hotgen Biotech Co., Ltd (SHA: 688068) announced that it has received clinical trial approval...

Company Drug

Merck Initiates Phase III waveLINE-010 Study for Zilovertamab Vedotin in DLBCL

Fineline Cube Feb 7, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced the initiation of...

Company Drug

Chipscreen Biosciences Gains NMPA Approval for Epidaza Phase III Study

Fineline Cube Feb 7, 2025

China-based Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that it has received approval from...

Company Drug

Alphamab and CSPC Gain NMPA Approval for JSKN003 Phase III Trial in HER2-Positive Breast Cancer

Fineline Cube Feb 7, 2025

Chinese partners Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that...

Company Drug

Gene Cradle’s GC310 Receives Tacit Approval from NMPA for Wilson’s Disease

Fineline Cube Feb 7, 2025

Beijing-based gene therapy specialist Gene Cradle announced that it has received tacit clinical approval from...

Posts pagination

1 … 172 173 174 … 621

Recent updates

  • Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials
  • InnoCare Pharma’s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials
  • Betta Pharma Secures NMPA Approval for Beizeting, First Domestic Pertuzumab Biosimilar in China
  • Kelun-Biotech’s Jiatailai Secures Fourth NMPA Approval for HR+/HER2- Breast Cancer Indication
  • Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials

Company Drug

InnoCare Pharma’s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials

Company Drug

Betta Pharma Secures NMPA Approval for Beizeting, First Domestic Pertuzumab Biosimilar in China

Company Drug

Kelun-Biotech’s Jiatailai Secures Fourth NMPA Approval for HR+/HER2- Breast Cancer Indication

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.